5月21日，英派药业-B盘中下跌5.77%，报35.28港元，成交额511.1万港元。
消息面上，公司于5月13日以每股20.10港元定价登陆港交所，首日收报41.86港元，较招股价涨108.26%，此后连续多日维持高位震荡。经历上市后大幅上涨，股价自高点回落幅度已超15%，短期获利盘兑现压力显现。值得关注的是，公司仍处亏损阶段，2025年净亏损约2.96亿元，营收仅3825万元，尚无法覆盖高强度研发投入，基本面对高估值的支撑力度有限。
公司是一家基于合成致死机制的精准抗癌疗法企业，核心产品塞纳帕利已在中国获批上市并纳入医保目录，研发管线覆盖PARP1/2、ATR、WEE1等多个合成致死靶点。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.